Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

Hickey, Theresa E.; Robinson, James C.; Carroll, Jason S.; Tilley, Wayne D.

doi:10.1210/me.2012-1107

Cited by 247 publications

(244 citation statements)

References 132 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…The AR splice variants expressed in advanced prostate cancer are largely hormone independent transcription factors that contribute to the maintenance of AR signalling in an androgendeplete environment and are resistant to conventional antiandrogenic drugs as they lack a ligand binding domain, the docking site for these drugs. While the role of AR in breast cancer is still being defined, and AR is likely to exert tumour suppressive as well as oncogenic effects depending on the molecular subtype [23], several clinical trials employing antiandrogen therapy in the treatment of women with advanced breast cancer are underway (NCT00468715, NCT01597193, NCT00755885). In the current study, we provide evidence for the first time that C-terminal truncated ARVs recently discovered in prostate cancer cells are also expressed in breast cancer cell lines and in multiple human tissues.…”

Section: G C T a C T C T T C A G C A T T A G T C C T G T G A A G G A mentioning

confidence: 99%

“…In particular, the role of AR in breast carcinogenesis has been the topic of increasing interest over the past decade. While it is clear that AR is expressed in the large majority of breast cancers, controversy exists over its role, which appears to vary depending on the molecular subtype [23]. To date, studies examining the expression of ARVs in human tissues or malignancies other than the prostate have been limited.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

Hickey

Irvine

et al. 2014

HORM CANC

View full text Add to dashboard Cite

The androgen receptor (AR) is widely expressed in human tissues and has biological function in many male and female organs. In particular, the AR plays a critical role in the biology and pathology of the prostate gland. AR activity inhibits breast growth and has pleiotropic actions in breast cancer that are subtype-dependent. Expression of AR splice variants (ARVs) and their role in prostate carcinogenesis has been elucidated in recent studies. We hypothesised that ARVs are also expressed in breast cancers and other hormone sensitive tissues. Herein, the expression of five previously identified ARV transcripts with documented transcriptional capacity (AR-V1, -V3, -V4, -V7, and -V9) was examined in 6 breast (MFM223, MDA-MB-453, MDA-MB-231, ZR75

show abstract

Section: G C T a C T C T T C A G C A T T A G T C C T G T G A A G G A mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

Hickey

Irvine

et al. 2014

HORM CANC

View full text Add to dashboard Cite

show abstract

“…14 AR signaling exerts an antiestrogen, anti-proliferative influence under normal physiologic conditions, and this role may be sustained in ER-positive breast cancer cells. [15][16][17] On the contrary, AR signaling may also promote growth of a subset of ER-negative, AR-positive breast cancers with a molecular apocrine phenotype.…”

Section: Introductionmentioning

confidence: 99%

Prohibitin promotes androgen receptor activation in ER-positive breast cancer

Liu

Zhang

et al. 2017

Cell Cycle

View full text Add to dashboard Cite

Prohibitin (PHB) is an evolutionarily conserved protein with multiple functions in both normal and cancer cells. Androgen receptor (AR) was reported to act as a different role in the ER-positive and ER-negative breast cancer. However, little is known about the role of PHB and whether PHB could regulate AR expression in the ER-positive breast cancer. Here, we determined the expression and clinical outcomes of PHB in breast cancer samples using 121 breast cancer tissues and published databases, and investigated the role of PHB in breast cancer cell growth, apoptosis and cell cycle arrest in the ER-positive breast cancer cells. We obtained the expression of PHB is significantly low in breast cancer samples, and low PHB expression positively correlated with poor prognosis of breast cancer. We detected that PHB could inhibit breast cancer cell proliferation, change cell cycle distribution and promote cell apoptosis in the ER-positive breast cancer cells. Moreover, we found PHB could significantly increase AR expression in both mRNA and protein levels in the ER-positive breast cancer cells. Additionally, a significant positive correlation between PHB and AR expression was identified in the 121 breast cancer tissues. PHB and AR expression are associated with prognosis in the ER-positive breast cancer patients. Our results indicate that PHB promotes AR activation in ER-positive breast cancer, making PHB and AR potential molecular targets for ER-positive breast cancer therapy.

show abstract

“…Studies of breast cancer risk by receptor subtype have shown inconsistent results (1). The importance of the androgen receptor (AR) as a prognostic factor and a possible treatment target in breast cancer is currently debated (2,3). Immunohistochemical (IHC) expression of AR is reported in 70% to 90% of all invasive breast cancers (4,5).…”

Section: Introductionmentioning

confidence: 99%

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort

Elebro

Butt

Dorkhan

et al. 2014

Cancer Causes Control

View full text Add to dashboard Cite

Link to publication Citation for published version (APA): Elebro, K., Butt, S., Dorkhan, M., Jernström, H., & Borgquist, S. (2014). Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes and Control, 25(8), 945-957. DOI: 10.1007/s10552-014-0394-2 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.• You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal

show abstract

Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?

Cited by 247 publications

References 132 publications

Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues

Prohibitin promotes androgen receptor activation in ER-positive breast cancer

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort

Contact Info

Product

Resources

About